印刷

診療科・部門紹介
診療科・部門紹介

乳腺センター

乳腺センター

最終更新日 : 2021年5月12日

乳腺センターとは乳腺センターからのお願い診療科の特徴|診療・研究実績|スタッフ紹介
連携病院リスト乳腺科問診票NEW!これから乳がんの手術を受ける方へ乳がんと遺伝について医療従事者向け情報

診療・研究実績

乳腺外科

手術件数(2019年)

初回手術数(入院+外来) 1,231
 乳房温存 439
 乳房切除 791
 うち同時再建を伴う 190
  乳房操作なし 1
その他 224
 良性手術 51
 再発手術 69
 追加手術 82
 上記以外 22
1,445

手術数推移

がん研有明病院の原発乳癌手術

乳腺内科

年間新規患者数(術前・術後)

年間新規患者数(術前・術後)

年間新規患者数(再発・StageIV)

年間新規患者数(再発・StageIV)

年間再診患者数(延べ総数)

年間再診患者数(延べ総数)

年間稼働治験件数

年間稼働治験件数

新規治験受託件数

新規治験受託件数

乳腺センター研究実績

このページのTOPへ

2020年

  • Sakai T, Ueno T. Local management after neoadjuvant treatment for breast cancer. Chin Clin Oncol. 2020 Jun;9(3):34. doi: 10.21037/cco-20-164. Epub 2020 Jun 11. PMID: 32576022.
  • Inari H, Teruya N, Kishi M, Horii R, Akiyama F, Takahashi S, Ito Y, Ueno T, Iwase T, Ohno S. Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. Cancers (Basel). 2020 Sep 15;12(9):E2633. doi: 10.3390/cancers12092633. PMID: 32942650.
  • Bando H, Kataoka A, Tamaki K, Kobayashi M, Tamura N, Ozawa M, Kawano J, Fukatsu Y, Kitano A, Shiota K, Yamauchi H. Physician's knowledge, attitudes and practice pattern for breast cancer diagnosed during pregnancy: a survey among breast care specialists in Japan. Breast Cancer. 2020 Sep;27(5):796-802. doi: 10.1007/s12282-020-01118-8. Epub 2020 Jun 26. PMID: 32592140.
  • Fukuoka M, Ueno T, Yoshida K, Kikuchi M, Takeuchi K, Ohno S. Breast castleman disease. Breast J. 2020 May 29. doi: 10.1111/tbj.13902. Epub ahead of print. PMID: 32469112.
  • Horii R, Tsuda H, Masuda S, Sugita H, Togashi K, Ohno S, Akiyama F. Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer. Breast Cancer. 2020 May 21. doi: 10.1007/s12282-020-01108-w. Epub ahead of print. PMID: 32440959.
  • Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, Iwata H. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast Cancer. 2020 Jan;27(1):4-8. doi: 10.1007/s12282-019-01030-w. Epub 2019 Dec 12. PMID: 31832890.
  • Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. PMID: 32170634; PMCID: PMC7103001.
  • Izumori A, Kokubu Y, Sato K, Gomi N, Morizono H, Sakai T, Horii R, Akiyama F, Iwase T, Ohno S. Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities. Breast Cancer. 2020 Jan;27(1):129-139. doi: 10.1007/s12282-019-01003-z. Epub 2019 Aug 12. PMID: 31407151; PMCID: PMC6954142.
  • Kaneyasu T, Mori S, Yamauchi H, Ohsumi S, Ohno S, Aoki D, Baba S, Kawano J, Miki Y, Matsumoto N, Nagasaki M, Yoshida R, Akashi-Tanaka S, Iwase T, Kitagawa D, Masuda K, Hirasawa A, Arai M, Takei J, Ide Y, Gotoh O, Yaguchi N, Nishi M, Kaneko K, Matsuyama Y, Okawa M, Suzuki M, Nezu A, Yokoyama S, Amino S, Inuzuka M, Noda T, Nakamura S. Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. NPJ Breast Cancer. 2020 Jun 12;6:25. doi: 10.1038/s41523-020-0163-1. PMID: 32566746; PMCID: PMC7293299.
  • Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. PMID: 31811519; PMCID: PMC7196081.
  • Lin CH, Yap YS, Lee KH, Yeo W, Ueno T, Li H, Huang SM, Lu YS. Response to Sung, Rosenberg, and Yang. J Natl Cancer Inst. 2020 May 1;112(5):547-548. doi: 10.1093/jnci/djz191. PMID: 31545369; PMCID: PMC7225667.
  • Luangxay T, Osako T, Yonekura R, Sugiura Y, Kikuchi M, Gomi N, Ueno T, Ohno S, Machinami R, Takeuchi K, Akiyama F. Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. Pathol Res Pract. 2020 Feb;216(2):152750. doi: 10.1016/j.prp.2019.152750. Epub 2019 Nov 19. PMID: 31784095.
  • Masuda T, Noda M, Kitagawa A, Hu Q, Fujii A, Ito S, Kosai K, Ando Y, Matsumoto Y, Ohtsu H, Uchida H, Ohno S, Mimori K. The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. Anticancer Res. 2020 Jul;40(7):3733-3742. doi: 10.21873/anticanres.14362. PMID: 32620612.
  • Masuda T, Ueo H, Kai Y, Noda M, Hu Q, Sato K, Fujii A, Hayashi N, Tsuruda Y, Otsu H, Kuroda Y, Eguchi H, Ohno S, Mimori K, Ueo H. N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study. Int J Mol Sci. 2020 Jan 14;21(2):511. doi: 10.3390/ijms21020511. PMID: 31947504; PMCID: PMC7013704.
  • Masuda T, Noda M, Kogawa T, Kitagawa D, Hayashi N, Jomori T, Nakanishi Y, Nakayama KI, Ohno S, Mimori K. Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer. Cancer Sci. 2020 Mar;111(3):924-931. doi: 10.1111/cas.14306. Epub 2020 Feb 11. PMID: 31943636; PMCID: PMC7060487.
  • Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat. 2020 Feb;180(1):135-146. doi: 10.1007/s10549-020-05524-6. Epub 2020 Jan 17. PMID: 31953696; PMCID: PMC7031180.
  • Nakajima E, Iwase T, Miyagi Y, Fujita T, Ikeda N, Ishikawa T, Iwata H. Association of Parity and Infant Feeding Method with Breast Density on Mammography. Acad Radiol. 2020 Feb;27(2):e24-e26. doi: 10.1016/j.acra.2019.03.020. Epub 2019 May 6. PMID: 31072765.
  • O'Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, Barrios C, Ueno T. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep. 2020 Jul 8;10(1):11203. doi: 10.1038/s41598-020-66980-0. PMID: 32641747; PMCID: PMC7343788.
  • Ohishi Y, Mitsuda A, Ejima K, Morizono H, Yano T, Yokoyama M, Takeuchi K, Fujiwara M, Nemoto T, Minabe T. Breast implant-associated anaplastic large-cell lymphoma: first case detected in a Japanese breast cancer patient. Breast Cancer. 2020 May;27(3):499-504. doi: 10.1007/s12282-020-01064-5. Epub 2020 Feb 24. PMID: 32095988; PMCID: PMC7196092.
  • Okamoto M, Tajiri W, Ueo H, Masuda T, Ijichi H, Koga C, Nakamura Y, Taguchi K, Ohno S, Tokunaga E. Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice. Anticancer Res. 2020 Jun;40(6):3315-3323. doi: 10.21873/anticanres.14314. PMID: 32487627.
  • Rubio IT, Kontos M, Vrancken-Peeters M, Rouzier R, Skandarajah AR, Galimberti V, Kroman N, Caballero C, Ohno S; BIG Task Force Surgical Trials. Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. Eur J Surg Oncol. 2020 Apr;46(4 Pt A):501-503. doi: 10.1016/j.ejso.2019.11.503. Epub 2019 Nov 20. PMID: 31785986.
  • Suzuki R, Yoshida M, Oguchi M, Yoshioka Y, Tokumasu K, Osako T, Ono S, Ueno T, Miyagi Y. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res. 2020 May 22;61(3):440-446. doi: 10.1093/jrr/rraa005. PMID: 32163143; PMCID: PMC7299253.
  • Tokunaga E, Ijichi H, Tajiri W, Masuda T, Takizawa K, Ueo H, Koga C, Tanaka J, Nakamura Y, Ohno S, Taguchi K, Okamoto M. The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution. Breast Cancer. 2020 May 29. doi: 10.1007/s12282-020-01116-w. Epub ahead of print. PMID: 32472474.
  • Tsuda H, Tsugawa K, Akiyama F, Horii R, Kurosumi M, Moriya T, Takano T, Takei H, Nakayama T, Miyagi Y, Yamauchi C, Yamashita T, Aogi K, Mukai H, Sugie T, Iwata H, Masuda S. Correction to: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition). Breast Cancer. 2020 Jul;27(4):792. doi: 10.1007/s12282-020-01106-y. Erratum for: Breast Cancer. 2020 May;27(3):309-321. PMID: 32430856.
  • Ueno T. Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer. Chin Clin Oncol. 2020 Jun;9(3):35. doi: 10.21037/cco-20-165. PMID: 32594749.
  • Yamamoto Y, Ueno T. Focused issue "Neoadjuvant/adjuvant treatment for early breast cancer". Chin Clin Oncol. 2020 Jun;9(3):26. doi: 10.21037/cco.2020.03.09. Epub 2020 May 15. PMID: 32434343.
  • Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M; JBCRG-C01 Collaborative Group. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer. 2020 Jul;27(4):631-641. doi: 10.1007/s12282-020-01057-4. Epub 2020 Feb 14. PMID: 32060785; PMCID: PMC7297820.
  • Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol. 2020 Jan 24;50(1):3-11. doi: 10.1093/jjco/hyz119. PMID: 31821506; PMCID: PMC6978625.
  • Shibayama T, Low SK, Ono M, Kobayashi T, Kobayashi K, Fukada I, Ito Y, Ueno T, Ohno S, Nakamura Y, Takahashi S. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr;180(2):331-341. doi: 10.1007/s10549-019-05512-5. Epub 2020 Feb 4. PMID: 32020432.
  • Hirai T, Nemoto A, Ito Y, Matsuura M. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer. Breast Cancer Res Treat. 2020 May;181(1):189-198. doi: 10.1007/s10549-020-05615-4. Epub 2020 Apr 3. PMID: 32246379.
  • Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020 Sep;39(3):711-720. doi: 10.1007/s10555-020-09881-y. PMID: 32399646.
  • Iwamoto T, Hara F, Uemura Y, Mukai H, Watanabe T, Ohashi Y. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. Breast Cancer Res Treat. 2020 Jul;182(2):325-332. doi: 10.1007/s10549-020-05692-5. Epub 2020 May 28. PMID: 32462261.
  • Iwata H, Inoue K, Kaneko K, Ito Y, Tsugawa K, Hasegawa A, Nakagawa S, Kuratomi H, Tamura K. Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol. 2020 Feb 17;50(2):223. doi: 10.1093/jjco/hyz208. Erratum for: Jpn J Clin Oncol. 2019 Dec 27;49(12):1083-1091. PMID: 31950142; PMCID: PMC7025717.
  • Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. PMID: 31811519; PMCID: PMC7196081.
  • Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat. 2020 Feb;180(1):135-146. doi: 10.1007/s10549-020-05524-6. Epub 2020 Jan 17. PMID: 31953696; PMCID: PMC7031180.
  • Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PMID: 31825192; PMCID: PMC7458671.
  • Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H, Tokunaga S, Shimokawa M, Ito Y, Saeki T. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer. 2020 Jan;27(1):122-128. doi: 10.1007/s12282-019-01001-1. Epub 2019 Aug 12. PMID: 31407150; PMCID: PMC6954145.
  • Ohsumi S, Kiyoto S, Takahashi M, Hara F, Takashima S, Aogi K, Matsuda M, Yamamura N, Doi M. Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. Support Care Cancer. 2020 May 9. doi: 10.1007/s00520-020-05506-w. Epub ahead of print. PMID: 32388615.
  • Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer. 2020 May;27(3):340-346. doi: 10.1007/s12282-020-01054-7. Epub 2020 Feb 11. PMID: 32043218; PMCID: PMC7196086.
  • Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020 May;27(3):322-331. doi: 10.1007/s12282-020-01085-0. Epub 2020 Apr 2. PMID: 32240526.
  • Takano T. The era of meta-analyses-based recommendations: how were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established? Breast Cancer. 2020 May;27(3):332-333. doi: 10.1007/s12282-020-01099-8. PMID: 32342405.
  • Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020 Jun 8;21(1):503. doi: 10.1186/s13063-020-04408-w. Erratum for: Trials. 2020 May 7;21(1):391. PMID: 32513251; PMCID: PMC7278203.
  • Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020 May 7;21(1):391. doi: 10.1186/s13063-020-04341-y. Erratum in: Trials. 2020 Jun 8;21(1):503. PMID: 32381018; PMCID: PMC7206765.
  • Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoiu M, Masuda N. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Cancer Sci. 2020 Sep;111(9):3313-3326. doi: 10.1111/cas.14554. Epub 2020 Jul 28. PMID: 32619077; PMCID: PMC7469771.
  • Yokokawa T, Suzuki K, Sugisaki T, Kobayashi K, Shouji D, Watanabe H, Kawakami K, Takiguchi T, Aoyama T, Kobayashi K, Takahashi S, Ito Y, Ohno S, Hama T. Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy. Anticancer Res. 2020 Feb;40(2):915-921. doi: 10.21873/anticanres.14024. PMID: 32014935.

2019年

  • Sakai T, Ozkurt E, DeSantis S, Wong SM, Rosenbaum L, Zheng H, Golshan M. National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat. 2019 Nov;178(1):161-167. doi: 10.1007/s10549-019-05363-0. Epub 2019 Jul 19. PMID: 31325072.
  • Özkurt E, Sakai T, Wong SM, Tukenmez M, Golshan M. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? Ann Surg Oncol. 2019 Oct;26(10):3260-3268. doi: 10.1245/s10434-019-07534-1. Epub 2019 Jul 24. PMID: 31342356.
  • Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674. Erratum in: Ann Oncol. 2019 Oct;30(10):1674. Erratum in: Ann Oncol. 2020 Sep 7;: PMID: 31161190.
  • Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7. PMID: 30734152; PMCID: PMC6694038.
  • Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS; Asian Breast Cancer Cooperative Group. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306. doi: 10.1093/jnci/djz090. PMID: 31093668; PMCID: PMC6910158.
  • Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. PMID: 31361400; PMCID: PMC6745863.
  • Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS; Asian Breast Cancer Cooperative Group. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019 Oct;177(3):549-559. doi: 10.1007/s10549-019-05318-5. Epub 2019 Jul 4. PMID: 31270763.
  • Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer. 2019 Sep;26(5):651. doi: 10.1007/s12282-019-00984-1. Erratum for: Breast Cancer. 2019 Sep;26(5):637-650. PMID: 31168692; PMCID: PMC6828135.
  • Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer. 2019 Sep;26(5):637-650. doi: 10.1007/s12282-019-00970-7. Epub 2019 May 24. Erratum in: Breast Cancer. 2019 Jun 5;: PMID: 31127500; PMCID: PMC6694088.
  • Nakajima E, Iwase T, Miyagi Y, Fujita T, Ikeda N, Ishikawa T, Iwata H. Association of Parity and Infant Feeding Method with Breast Density on Mammography. Acad Radiol. 2020 Feb;27(2):e24-e26. doi: 10.1016/j.acra.2019.03.020. Epub 2019 May 6. PMID: 31072765.
  • Yonekura R, Osako T, Iwase T, Ogiya A, Ueno T, Kitagawa M, Ohno S, Akiyama F. Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2019 Feb;174(1):103-111. doi: 10.1007/s10549-018-5068-4. Epub 2018 Nov 24. PMID: 30474777.
  • Ohno S, Mukai H, Narui K, Hozumi Y, Miyoshi Y, Yoshino H, Doihara H, Suto A, Tamura M, Morimoto T, Zaha H, Chishima T, Nishimura R, Ishikawa T, Uemura Y, Ohashi Y. Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat. 2019 Aug;176(3):631-635. doi: 10.1007/s10549-019-05276-y. Epub 2019 May 21. PMID: 31115845.
  • Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res. 2019 Jun 15;25(12):3581-3588. doi: 10.1158/1078-0432.CCR-18-2521. Epub 2019 Mar 12. PMID: 30862692.
  • Robertson JFR, Jiang Z, Di Leo A, Ohno S, Pritchard KI, Ellis M, Bradbury I, Campbell C. A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer. 2019 Nov;26(6):703-711. doi: 10.1007/s12282-019-00973-4. Epub 2019 May 11. PMID: 31079343; PMCID: PMC6821663.
  • Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers. Breast Cancer. 2019 Nov;26(6):846-851. doi: 10.1007/s12282-019-00971-6. Epub 2019 Apr 12. PMID: 30980249; PMCID: PMC6821909.
  • Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. PMID: 30962956; PMCID: PMC6435245.
  • Lin CH, Yap YS, Lee KH, Yeo W, Ueno T, Li H, Huang SM, Lu YS. Response to Sung, Rosenberg, and Yang. J Natl Cancer Inst. 2020 May 1;112(5):547-548. doi: 10.1093/jnci/djz191. PMID: 31545369; PMCID: PMC7225667.
  • Luangxay T, Osako T, Yonekura R, Sugiura Y, Kikuchi M, Gomi N, Ueno T, Ohno S, Machinami R, Takeuchi K, Akiyama F. Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. Pathol Res Pract. 2020 Feb;216(2):152750. doi: 10.1016/j.prp.2019.152750. Epub 2019 Nov 19. PMID: 31784095.
  • Rubio IT, Kontos M, Vrancken-Peeters M, Rouzier R, Skandarajah AR, Galimberti V, Kroman N, Caballero C, Ohno S; BIG Task Force Surgical Trials. Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. Eur J Surg Oncol. 2020 Apr;46(4 Pt A):501-503. doi: 10.1016/j.ejso.2019.11.503. Epub 2019 Nov 20. PMID: 31785986.
  • Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol. 2020 Jan 24;50(1):3-11. doi: 10.1093/jjco/hyz119. PMID: 31821506; PMCID: PMC6978625.
  • Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. PMID: 32170634; PMCID: PMC7103001.
  • Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M. Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. Int J Mol Sci. 2019 Feb 24;20(4):984. doi: 10.3390/ijms20040984. PMID: 30813476; PMCID: PMC6412499.
  • Sato A, Sakai T, Iwase T, Kano F, Kimura K, Ogiya A, Koizumi M, Tanabe M, Horii R, Akiyama F, Ueno T, Ohno S. Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence. Radiat Oncol. 2019 Sep 2;14(1):159. doi: 10.1186/s13014-019-1367-0. PMID: 31477153; PMCID: PMC6720389.
  • Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H, Tokunaga S, Shimokawa M, Ito Y, Saeki T. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer. 2020 Jan;27(1):122-128. doi: 10.1007/s12282-019-01001-1. Epub 2019 Aug 12. PMID: 31407150; PMCID: PMC6954145.
  • Iwata H, Inoue K, Kaneko K, Ito Y, Tsugawa K, Hasegawa A, Nakagawa S, Kuratomi H, Tamura K. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol. 2019 Dec 27;49(12):1083-1091. doi: 10.1093/jjco/hyz135. Erratum in: Jpn J Clin Oncol. 2020 Feb 17;50(2):223. PMID: 31612909; PMCID: PMC6935297.
  • Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. PMID: 31811519; PMCID: PMC7196081.
  • Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, Hara F, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Huang X, Iwata H. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. Int J Clin Oncol. 2019 Mar;24(3):262-273. doi: 10.1007/s10147-018-1359-3. Epub 2018 Nov 3. PMID: 30392115; PMCID: PMC6399170.
  • Hara F, Tajima K, Tanabe K. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncol. 2019 Apr;15(12):1353-1361. doi: 10.2217/fon-2018-0957. Epub 2019 Feb 15. PMID: 30767568.

2018年

  • Shimazu K, Sato N, Ogiya A, Sota Y, Yotsumoto D, Ishikawa T, Nakamura S, Kinoshita T, Tsuda H, Ohi Y, Akiyama F, Noguchi S. Intraoperative Nomograms, Based on One-Step Nucleic Acid Amplification, for Prediction of Non-sentinel Node Metastasis and Four or More Axillary Node Metastases in Breast Cancer Patients with Sentinel Node Metastasis. Ann Surg Oncol. 2018 Sep;25(9):2603-2611. doi: 10.1245/s10434-018-6633-0. Epub 2018 Jul 5. PMID: 29978372; PMCID: PMC6097722.
  • Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Med. 2018 Jun 14;7(7):3044–56. doi: 10.1002/cam4.1600. Epub ahead of print. PMID: 29905023; PMCID: PMC6051169.
  • Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Med. 2018 Jun;7(6):2442-2451. doi: 10.1002/cam4.1516. Epub 2018 May 7. PMID: 29733541; PMCID: PMC6010720.
  • Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. PMID: 29531841; PMCID: PMC5844383.
  • Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. PMID: 30032243; PMCID: PMC7360146.
  • Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M, Kira A, Takatsuka Y, Egawa C, Suwa H, Ohno S, Miyoshi Y. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018 Oct 16;18(1):982. doi: 10.1186/s12885-018-4888-2. PMID: 30326862; PMCID: PMC6191898.
  • Sugihara T, Koizumi M, Hayakawa K, Ito Y, Sata N. Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab. Clin Nucl Med. 2018 May;43(5):365-366. doi: 10.1097/RLU.0000000000002058. PMID: 29517548.
  • Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Gomi N, Kokubu Y, Oikado K, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Sata N, Ito Y. Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. Radiology. 2018 Jan;286(1):49-57. doi: 10.1148/radiol.2017161548. Epub 2017 Jul 24. PMID: 28737968.
  • Inoue H, Horii R, Ito Y, Iwase T, Ohno S, Akiyama F. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. Breast Cancer. 2018 May;25(3):268-274. doi: 10.1007/s12282-017-0822-8. Epub 2017 Nov 28. PMID: 29185202.
  • Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23. PMID: 29698927.
  • Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31. PMID: 29500843; PMCID: PMC5980117.

2017年

  • Ogiya A, Yamazaki K, Horii R, Shien T, Horimoto Y, Masuda N, Inao T, Hosoda M, Ishida N, Osako T, Takahashi M, Endo Y, Miyoshi Y, Yasojima H, Tomioka N, Yamashita H; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 2017 May;24(3):473-482. doi: 10.1007/s12282-016-0730-3. Epub 2016 Sep 15. Erratum in: Breast Cancer. 2017 Jul;24(4):642. PMID: 27628678.
  • Shimoyama K, Osako T, Mitsuhashi T, Akiyama F, Iwase T. Lesion Size on Ultrasonography Predicts Potential Invasion in Ductal Carcinoma in situ Preoperatively Diagnosed by Breast Needle Biopsy. Acta Med Okayama. 2017 Jun;71(3):233-240. doi: 10.18926/AMO/55206. PMID: 28655943.
  • Inari H, Shimizu S, Suganuma N, Yoshida T, Nakayama H, Yamanaka T, Yamanaka A, Rino Y, Masuda M. A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women. Breast Cancer. 2017 Jan;24(1):98-103. doi: 10.1007/s12282-016-0678-3. Epub 2016 Feb 11. Erratum in: Breast Cancer. 2018 Jan 10;: PMID: 26868519.
  • Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Yamanaka A, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions. BMC Cancer. 2017 Feb 27;17(1):160. doi: 10.1186/s12885-017-3154-3. PMID: 28241804; PMCID: PMC5330119.
  • Inari H, Suganuma N, Kawachi K, Yoshida T, Yamanaka T, Nakamura Y, Yoshihara M, Nakayama H, Masudo K, Oshima T, Yokose T, Rino Y, Shimizu S, Miyagi Y, Masuda M. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. Breast Cancer. 2017 Nov;24(6):748-755. doi: 10.1007/s12282-017-0774-z. Epub 2017 Apr 19. PMID: 28425014.
  • Abe T, Fukada I, Shiga T, Morizono H, Ikebata K, Shibayama T, Kobayashi K, Iwase T, Ohno S, Ito Y. A Case of Recurrent Breast Cancer Identified by Pulmonary Tumor Thrombotic Microangiopathy. Case Rep Oncol. 2017 Jul 11;10(2):620-626. doi: 10.1159/000477842. PMID: 28868021; PMCID: PMC5567112.
  • Yokoe T, Fukada I, Kobayashi K, Shibayama T, Miyagi Y, Yoshida A, Iwase T, Ohno S, Ito Y. Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review. Case Rep Oncol. 2017 Jul 11;10(2):605-612. doi: 10.1159/000477897. PMID: 28868019; PMCID: PMC5567006.
  • Takahashi S, Kobayashi T, Tomomatsu J, Ito Y, Oda H, Kajitani T, Kakizume T, Tajima T, Takeuchi H, Maacke H, Esaki T. LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. Cancer Chemother Pharmacol. 2017 Jan;79(1):131-138. doi: 10.1007/s00280-016-3214-4. Epub 2016 Dec 9. PMID: 27942917; PMCID: PMC5225197.
  • Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest New Drugs. 2017 Dec;35(6):791-799. doi: 10.1007/s10637-017-0486-4. Epub 2017 Jun 29. PMID: 28660549; PMCID: PMC5694520.
  • Watanabe J, Ito Y, Saeki T, Masuda N, Takano T, Takao S, Nakagami K, Tsugawa K, Nakagawa S, Kanatani K, Nakayama T. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo. 2017 May-Jun;31(3):493-500. doi: 10.21873/invivo.11088. PMID: 28438884; PMCID: PMC5461466.
  • Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, Hatake K, Sata N. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med. 2017 Dec;31(10):719-725. doi: 10.1007/s12149-017-1202-3. Epub 2017 Sep 1. PMID: 28864931; PMCID: PMC5691120.
  • Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23. PMID: 28337663.
  • Nakayama Y, Ito Y, Tanabe M, Takahashi S. Omission of dexamethasone from antiemetic treatment for highly emetogenic chemotherapy in breast cancer patients with hepatitis B infection or diabetes mellitus. J Community Support Oncol. 2016 May;14(5):210-4. doi: 10.12788/jcso.0256. PMID: 27258053.
  • Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, JagieŁŁo-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30. Erratum in: Lancet Oncol. 2019 Feb;20(2):e71-e72. PMID: 28576675; PMCID: PMC5549667.
  • Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. Breast. 2017 Oct;35:78-84. doi: 10.1016/j.breast.2017.06.015. Epub 2017 Jun 27. PMID: 28662406.
  • Araki K, Miyoshi Y. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2017 Jan 19;376(3):288. doi: 10.1056/NEJMc1615255. PMID: 28102647.
  • Fukada I, Ito Y, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel. PLoS One. 2017 Sep 12;12(9):e0184322. doi: 10.1371/journal.pone.0184322. PMID: 28898275; PMCID: PMC5595337.

2016年

  • Fukuda T, Horii R, Gomi N, Miyagi Y, Takahashi S, Ito Y, Akiyama F, Ohno S, Iwase T. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus. 2016 Feb 24;5:152. doi: 10.1186/s40064-016-1800-x. PMID: 27026849; PMCID: PMC4766139.
  • Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Kinoshita T, Nakamura S, Tokuda Y. Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry. Breast Cancer Res Treat. 2016 Nov;160(1):163-172. doi: 10.1007/s10549-016-3984-8. Epub 2016 Sep 19. PMID: 27647460; PMCID: PMC5050233.
  • Makita M, Akiyama F, Gomi N, Iwase T. Mammary ductoscopy and watchful follow-up substitute microdochectomy in patients with bloody nipple discharge. Breast Cancer. 2016 Mar;23(2):242-51. doi: 10.1007/s12282-014-0561-z. Epub 2014 Aug 24. PMID: 25150843.
  • Makita M, Sakai T, Ogiya A, Kitagawa D, Morizono H, Miyagi Y, Iijima K, Iwase T. Optimal surveillance for postoperative metastasis in breast cancer patients. Breast Cancer. 2016 Mar;23(2):286-94. doi: 10.1007/s12282-014-0571-x. Epub 2014 Oct 8. PMID: 25294313.
  • Ogiya A, Kimura K, Nakashima E, Sakai T, Miyagi Y, Iijima K, Morizono H, Makita M, Horii R, Akiyama F, Iwase T. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital. Breast Cancer. 2016 Mar;23(2):318-22. doi: 10.1007/s12282-014-0576-5. Epub 2014 Nov 7. PMID: 25376341.
  • Sakai T, Iwase T, Teruya N, Kataoka A, Kitagawa D, Nakashima E, Ogiya A, Miyagi Y, Iijima K, Morizono H, Makita M, Gomi N, Oguchi M, Ito Y, Horii R, Akiyama F, Ohno S. Surgical excision without whole breast irradiation for complete resection of ductal carcinoma in situ identified using strict, unified criteria. Am J Surg. 2017 Jul;214(1):111-116. doi: 10.1016/j.amjsurg.2016.10.024. Epub 2016 Nov 30. PMID: 27964923.
  • Ishida N, Araki K, Sakai T, Kobayashi K, Kobayashi T, Fukada I, Hosoda M, Yamamoto M, Ichinokawa K, Takahashi S, Iwase T, Ito Y, Yamashita H. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience. Breast Cancer. 2016 Jul;23(4):617-23. doi: 10.1007/s12282-015-0612-0. Epub 2015 Apr 21. PMID: 25896598.
  • Ohno S. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. Clin Breast Cancer. 2016 Aug;16(4):238-46. doi: 10.1016/j.clbc.2016.03.001. Epub 2016 Mar 12. PMID: 27151773.
  • Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T, Hozumi Y, Yasuda Y, Hatake K. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today. 2016 Jul;46(7):821-6. doi: 10.1007/s00595-015-1252-x. Epub 2015 Oct 14. PMID: 26467559.
  • Fukada I, Araki K, Kobayashi K, Kobayashi T, Horii R, Akiyama F, Takahashi S, Iwase T, Ito Y. Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes. Oncol Lett. 2016 Jul;12(1):663-669. doi: 10.3892/ol.2016.4627. Epub 2016 May 25. PMID: 27347197; PMCID: PMC4907289.
  • Fukada I, Araki K, Kobayashi K, Shibayama T, Hatano M, Takahashi S, Iwase T, Ohno S, Ito Y. Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer. Springerplus. 2016 Sep 15;5(1):1582. doi: 10.1186/s40064-016-3280-4. PMID: 27652155; PMCID: PMC5025414.
  • Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S, Hatake K, Hozumi Y, Sata N, Ito Y. Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer. PLoS One. 2016 Sep 15;11(9):e0162616. doi: 10.1371/journal.pone.0162616. PMID: 27631393; PMCID: PMC5025211.
  • Kobayashi T, Tomomatsu J, Fukada I, Shibayama T, Teruya N, Ito Y, Iwase T, Ohno S, Takahashi S. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study. BMC Cancer. 2016 Jul 7;16:404. doi: 10.1186/s12885-016-2436-5. PMID: 27389013; PMCID: PMC4936231.
  • Yamauchi C, Sekiguchi K, Nishioka A, Arahira S, Yoshimura M, Ogo E, Oguchi M, Ito Y, Mukai H. The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2015 edition. Breast Cancer. 2016 May;23(3):378-90. doi: 10.1007/s12282-016-0672-9. Epub 2016 Feb 16. PMID: 26883534.